Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | CCR9 | P51686 | 2/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MASP2 | O00187 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376337 | 0.92 | LMNA (0.46) | LMNASMN1; SMN2DRD2TYMSGRM1 | |
| SCHEMBL3375860 | 0.92 | LMNA (0.46) | LMNASMN1; SMN2DRD2TYMSGRM1 | |
| SCHEMBL3378400 | 0.90 | LMNA (0.48) | LMNASMN1; SMN2TYMSGRM1GRM4 | |
| SCHEMBL3377243 | 0.88 | LMNA (0.47) | LMNASMN1; SMN2GRM1GRM4DPP4 | |
| SCHEMBL3377842 | 0.86 | LMNA (0.50) | LMNASMN1; SMN2DRD2CCR9ALDH1A1 | |
| SCHEMBL3376147 | 0.83 | CCR9 (0.44) | DRD2TYMSDPP4CCR9GALR3 | |
| SCHEMBL3376357 | 0.82 | LMNA (0.47) | LMNASMN1; SMN2TYMSGRM1GRM4 | |
| SCHEMBL3374479 | 0.82 | LMNA (0.47) | LMNASMN1; SMN2TYMSGRM1GRM4 | |
| SCHEMBL3374766 | 0.80 | DPP4 (0.51) | LMNASMN1; SMN2TYMSGRM1GRM4 | |
| SCHEMBL3376240 | 0.80 | LMNA (0.45) | LMNASMN1; SMN2TYMSGRM1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517886-B1 | NOVEL PHTHALAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-7132455-B2 | Phthalamide derivatives | BAYER CROPSCIENCE AG (DE) | 2006-11-07 | — | — | US | disclosed |
| US-20060035967-A1 | Novel phthalamide derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| EP-1517886-A1 | NOVEL PHTHALAMIDE DERIVATIVES | Bayer CropScience AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000796-A1 | NOVEL PHTHALAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035967-A1 | Novel phthalamide derivatives | HDAC1, HDAC2, CRY1 | LMNA 3512/4885SMN1; SMN2 3786/4885DRD2 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.